CEO and Co-Founder, Receptos
Co-Chair, Life Sciences Practice, Fenwick and West
Managing Partner, Triathalon Medical Ventures Fund II
Chief of Genetics, UC San Diego School of Medicine
Visiting Scholar, MIT
Senior Managing Partner, Aisling Capital Fund
President, Babson College
Founder and Chairman, Sycamore Networks
|
AVI Biopharma, the Portland, OR-based developer of RNA-based therapies, said today it has been awarded part of a $2.5 million contract from the U.S. Department of Defense to develop a drug for Duchenne Muscular Dystrophy. The contract, awarded to researchers at the Children’s National Medical Center in Washington D.C., will support animal studies to develop AVI-4658. AVI (NASDAQ: AVII) will serve as a subcontractor, the company said.
San Francisco · 6/7/12
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
